JP2024502295A - 遺伝子治療において交流電場を使用するための方法及び組成物 - Google Patents

遺伝子治療において交流電場を使用するための方法及び組成物 Download PDF

Info

Publication number
JP2024502295A
JP2024502295A JP2023539028A JP2023539028A JP2024502295A JP 2024502295 A JP2024502295 A JP 2024502295A JP 2023539028 A JP2023539028 A JP 2023539028A JP 2023539028 A JP2023539028 A JP 2023539028A JP 2024502295 A JP2024502295 A JP 2024502295A
Authority
JP
Japan
Prior art keywords
electric field
vector
cell
alternating electric
frequency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023539028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502295A5 (cg-RX-API-DMAC7.html
Inventor
タリ・ボロシン-セラ
リラチ・アヴィグドル
ヤーラ・ポラト
ヘレナ・マブラト
Original Assignee
ノボキュア ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノボキュア ゲーエムベーハー filed Critical ノボキュア ゲーエムベーハー
Publication of JP2024502295A publication Critical patent/JP2024502295A/ja
Publication of JP2024502295A5 publication Critical patent/JP2024502295A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36002—Cancer treatment, e.g. tumour
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023539028A 2020-12-24 2021-12-22 遺伝子治療において交流電場を使用するための方法及び組成物 Pending JP2024502295A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063130449P 2020-12-24 2020-12-24
US63/130,449 2020-12-24
PCT/IB2021/062198 WO2022137171A2 (en) 2020-12-24 2021-12-22 Methods and compositions for using alternating electric fields in gene therapy

Publications (2)

Publication Number Publication Date
JP2024502295A true JP2024502295A (ja) 2024-01-18
JP2024502295A5 JP2024502295A5 (cg-RX-API-DMAC7.html) 2025-01-07

Family

ID=80121763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023539028A Pending JP2024502295A (ja) 2020-12-24 2021-12-22 遺伝子治療において交流電場を使用するための方法及び組成物

Country Status (5)

Country Link
US (1) US20220203088A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267236B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502295A (cg-RX-API-DMAC7.html)
CN (1) CN116615268A (cg-RX-API-DMAC7.html)
WO (1) WO2022137171A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7886853B2 (ja) * 2020-09-18 2026-07-08 ノボキュア ゲーエムベーハー コロナウイルスを処置するための方法及び組成物
JP2025520663A (ja) * 2022-06-21 2025-07-03 ノボキュア ゲーエムベーハー 交流電場とcrispr-casシステムを用いた症状および疾患の治療システムおよび方法
CN115845254B (zh) * 2022-11-23 2024-02-02 湖南安泰康成生物科技有限公司 小细胞肺癌治疗系统以及交变电场发生装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200009376A1 (en) * 2018-07-03 2020-01-09 Edwin Chang Using Alternating Electric Fields to Increase Cell Membrane Permeability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
WO1999011771A1 (en) * 1997-09-04 1999-03-11 Science Research Laboratory, Inc. Cell separation using electric fields
SE9704076D0 (sv) * 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US7016725B2 (en) 2001-11-06 2006-03-21 Standen Ltd. Method and apparatus for destroying dividing cells
US8447395B2 (en) 2000-02-17 2013-05-21 Novocure Ltd Treating bacteria with electric fields
US20040092860A1 (en) * 2000-07-26 2004-05-13 Dev Nagendu B. Skin and muscle-targeted gene therapy by pulsed electrical field
WO2005115535A2 (en) 2004-04-23 2005-12-08 Novocure Ltd. Treating a tumor or the like with electric fields at different frequencies
CN102488967B (zh) * 2004-12-27 2016-03-30 诺沃库勒有限公司 利用电场从不同方向治疗肿瘤等
EP3143124B1 (en) * 2014-05-12 2025-01-22 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US20200308560A1 (en) * 2017-06-26 2020-10-01 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
KR102793500B1 (ko) * 2018-05-02 2025-04-14 그랜드 디케이드 디벨로프먼츠 리미티드 전기천공 시스템, 방법, 및 장치
WO2020047387A1 (en) * 2018-08-31 2020-03-05 Thomas Jefferson University In vivo genetic engineering of antigen responsive cells
CN113164525B (zh) * 2018-10-23 2025-03-14 利兰·斯坦福青年大学托管委员会 在基于干细胞的疗法中使用交变电场预防和治疗畸胎瘤形成

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200009376A1 (en) * 2018-07-03 2020-01-09 Edwin Chang Using Alternating Electric Fields to Increase Cell Membrane Permeability

Also Published As

Publication number Publication date
EP4267236A2 (en) 2023-11-01
EP4267236B1 (en) 2026-06-24
CN116615268A (zh) 2023-08-18
WO2022137171A2 (en) 2022-06-30
US20220203088A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
US10709797B2 (en) Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy
JP2022163182A (ja) 腫瘍溶解性ウイルスによるPTEN-Longの発現
US20220203088A1 (en) Methods And Compositions For Using Alternating Electric Fields In Gene Therapy
Kaur et al. Addressing the challenge: current and future directions in ovarian cancer therapy
Rouanet et al. Gene therapy for pancreatic cancer: specificity, issues and hopes
ES2743507T3 (es) Inmunoterapia resistente a fármaco para el tratamiento de un cáncer
McDonald et al. Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma
US12385067B2 (en) Compositions and therapeutic methods of microRNA gene delivery
CN101495156A (zh) 用于癌症和其他疾病的亲病灶性靶向基因递送系统
WO2021121166A1 (zh) 用于癌症治疗的多靶向siRNA
US20220040329A1 (en) Inducible expression cassette, and uses thereof
EP4342985A2 (en) Pharmaceutical composition for preventing or treating cancer comprising anticancer virus and hydroxyurea as effective components
KR20120132594A (ko) 마이크로rna를 이용한 조절을 통한 암 특이적 유전자 치료제
JP5486502B2 (ja) 癌治療用の多数の発現カセットを含む構造体
JP5550803B2 (ja) 新規アデノウイルスを用いた癌治療方法及び組成物
US20230390320A1 (en) Cancer-specific trans-splicing ribozyme expressing immune checkpoint inhibitor, and use thereor
CN118186004A (zh) 一种响应缺氧环境控制目的基因表达的系统及其用途
Kang et al. The piggyBac transposon is an integrating non‐viral gene transfer vector that enhances the efficiency of GDEPT
Alavi et al. Novel approaches and limitations in viral gene therapy of cancer diseases
Xu et al. Pancreatic cancer: gene therapy approaches and gene delivery systems
US20170247693A1 (en) Combinatorial treatment of chemotherapy and armed viruses targeting tumor
ITMI20011138A1 (it) Vettore e metodi di impiego per l'espressione selettiva di geni in siti di angiogenesi in vivo
Ichikawa et al. Effects of Inhalable Gene Drug Transfection as A Novel Gene Therapy for Non-Small Cell Lung Cancer and Malignant Pleural Mesothelioma
CN118286157A (zh) 一种用于原位和转移肺癌治疗的可吸入仿生脂质体及其制备方法和应用
Mishra et al. Gene Therapy for Treatment of Pancreatic Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260623